<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835623</url>
  </required_header>
  <id_info>
    <org_study_id>SP-001</org_study_id>
    <nct_id>NCT04835623</nct_id>
  </id_info>
  <brief_title>CEQUA for Sjogren's Syndrome Dry Eye</brief_title>
  <official_title>Effects of CEQUAâ„¢ on Objective and Subjective Dry Eye Findings Associated With Sjogren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Ophthalmic and Vision Research, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Ophthalmic and Vision Research, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to show that CEQUA (cyclosporine 0.09% ophthalmic&#xD;
      solution) improves symptoms of dry eye disease in a population of patients with Sjogren's&#xD;
      Syndrome diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all participants giving informed&#xD;
      consent will have an eye exam and will be asked about their medical history to determine&#xD;
      eligibility for the study. Eligible participants will continue to the second visit the same&#xD;
      day or up to 10 days later. During the second visit participants will answer questionnaires&#xD;
      about their eyes and have their vision, eyes, and tears examined. All participants will be&#xD;
      given CEQUA to use over the duration of the study. The same procedures will be repeated every&#xD;
      four weeks for 3 months total.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in total corneal staining</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Expanded NEI corneal staining scale ranging from 0 to 15</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in total conjunctival staining</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Expanded NEI conjunctival staining scale ranging from 0 to 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the score of dry eye questionnaires</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Dry eye questionnaire score ranging from 0 to 28</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dry Eye</condition>
  <condition>Dry Eye Syndromes</condition>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Cyclosporine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Cyclosporine 0.09% Ophthalmic Solution (Cequa), 1 drop, each eye, twice a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine 0.09% Ophthalmic Solution</intervention_name>
    <description>one drop each eye twice daily</description>
    <arm_group_label>Cyclosporine</arm_group_label>
    <other_name>Cequa Ophthalmic Product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Sjogren's Syndrome.&#xD;
&#xD;
          -  Self-reported complaints of ocular dryness for a period of at least 3 months&#xD;
&#xD;
          -  Best-corrected distance visual acuity of 20/25 or better in each eye.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of cyclosporine within the last 3 months.&#xD;
&#xD;
          -  Use of ocular steroid within the 3 months.&#xD;
&#xD;
          -  Previous history of treatment failure with cyclosporine.&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to the study medication or any of its&#xD;
             ingredients.&#xD;
&#xD;
          -  Use of any systemic or topical ocular medication that is known to cause or exacerbate&#xD;
             dry eye.&#xD;
&#xD;
          -  Any active ocular infection.&#xD;
&#xD;
          -  Severe or serious ocular condition in either eye or any other unstable medical&#xD;
             condition that may preclude study treatment or follow-up.&#xD;
&#xD;
          -  History or presence of chronic generalized systemic disease that might increase the&#xD;
             risk to the subject or confound the results of the study.&#xD;
&#xD;
          -  Currently pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Rocco Robilotto, OD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Ophthalmic and Vision Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George Zikos, OD, MS</last_name>
    <phone>212-650-4888</phone>
    <email>COVR@ea-ny.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Rocco Robilotto, OD, PhD</last_name>
    <phone>212-650-4888</phone>
    <email>COVR@ea-ny.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Ophthalmic and Vision Recearch</name>
      <address>
        <city>Manhattan</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Zikos, OD, MS</last_name>
      <phone>212-650-4888</phone>
      <email>COVR@ea-ny.com</email>
    </contact>
    <contact_backup>
      <last_name>John Rocco Robilotto, OD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>John Rocco Robilotto, OD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Zikos, OD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanish Patel, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

